What is

Blockmir Technology

The technology uses short highly modified oligonucleotides – Blockmirs – to block specific miRNA binding sites on individual mRNAs. This achieves gene specific upregulation on protein level and sets the Blockmir Technology apart from most other therapeutic modalities which aim to antagonize mRNA or protein activity. Blockmirs are agonists of gene expression and lead to physiologic upregulation of protein levels.


The Blockmir Technology is covered by a broad and dominant portfolio of issued patents. The patent estate covers the target mRNAs of more than 300 miRNAs – which means several thousands of different target mRNAs that can be upregulated individually. A composition of matter for a general Blockmir design with improved selectivity and potency is also granted.


Upregulation of therapeutically relevant proteins is applicable in a wide range of diseases spanning from cancer to rare genetic and metabolic disorders where even a small upregulation of a single protein can mean a world of difference for the patients. Blockmirs, sometimes called target protectors or protectomirs, have been used in more than 160 academic research programs worldwide, showing upregulation of many therapeutically relevant targets and underscoring the wide application of this technology.

Learn More

Disease areas and Pipeline

MJJ Biotech is striving to develop Therapeutic Blockmirs that can be used to treat a variety of diseases and conditions, including diseases of the liver, the CNS and the eye.

Disease Areas        Pipeline

Company Profile

Guangdong Maijinjia Biotechnologies Co., Ltd. is an innovative technology enterprise for antisense nucleic acid drugs jointly invested by China and Denmark with an international perspective, and has received investment from the Huangpu District Government Industry Fund in Guangzhou. The company has blockmir nucleic acid drug research and development technology and Dosevo nucleic acid drug screening technology with complete patent wall protection, and the company has global ownership of all related patents. The company's main team has over decades of experience in biopharmaceutical research and development entrepreneurship in the fields of small molecule RNAs, modified oligonucleotides, patents, clinical trials, biotechnology, and business management.

Field focus: Utilizing Blockmir technology to address clinical needs that cannot be met by existing marketed drugs for "central nervous system, ophthalmology, liver diseases, cardiovascular diseases, respiratory system diseases".


Join Us

Our research team consists of trained specialists in the fields of small RNA, modified oligonucleotides, patenting, clinical trials, biotechnology and business from different cultural backgrounds. We are driven by our mission and committed to impacting people's lives and improving human health on a global scale.